Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos
Open accessPublished version of a preprint
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Introduction: In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS—CoV-2 viral replication, but questions remained as to in-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19. Methods: We conducted a translational proof of concept randomized, double blind placebo controlled, dose response and parallel group study of IV efficacy in RT—polymerase chain reaction proven COVID 19 positive patients. Sixty-two patients were randomized to three treatment groups. (A) IV 6 mg regime, (B) IV 12 mg regime (given Q84 h for 2 weeks) (C, control) Lopinavir/Ritonavir. All groups plus standard of Care. Results: The Days to COVID negativity (DTN) was significantly and dose dependently reduced by IV (P = 0.0066). The DTN for Control were, = 9.1+/–5.2, for A 6.0 +/– 2.9 and for B 4.6 +/–3.2. Two way repeated measures ANOVA of ranked COVID 19 +/– scores at 0, 84, 168 and252h showed a significant IV treatment effect (P = 0.035) and time effect (P < 0.0001). IV also tended to increase SPO2% compared to controls, P = 0.073, 95% CI—0.39 to 2.59 and increased platelet count compared to C (P = 0.037) 95%CI 5.55—162.55 × 103/ml. The platelet count increase was inversely correlated to DTN (r = –0.52, P = 0.005). No SAE was reported. Conclusions: 12mg IV regime given twice a week may have superior efficacy over 6mg IV given twice a week, and certainly over the non IV arm of the study. IV should be considered for use in clinical management of SARS-COV2, and may find applications in prophylaxis in high risk areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Persistent Symptoms in Patients After Acute COVID-19
Carfì, A., Bernabei, R., Landi, F., & for the Gemelli Against COVID-19 Post-Acute Care Study Group (2020) · JAMA · doi:10.1001/jama.2020.12603 · Cited by 4,561
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Racial bias in pulse oximetry measurement
Sjoding, M. W., Dickson, R. P., Iwashyna, T. J., Gay, S. E., & Valley, T. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2029240 · Cited by 1,114
Research works printed but not linked: 18
- Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 · DOI · Paper page
- Cucinotta, 2020, WHO Declares COVID-19 a pandemic, Acta Bio Medica Atenei Parm, 91, 157
- Khullar, 2020, COVID-19 and the financial health of US hospitals, JAMA, 323, 2127, 10.1001/jama.2020.6269 · DOI · Paper page
- Heidary, 2020, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot (Tokyo), 73, 593, 10.1038/s41429-020-0336-z · DOI · Paper page
- Abiose, 1993, Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis, Lancet, 341, 130, 10.1016/0140-6736(93)90002-X · doi:10.1016/0140-6736(93)90002-x
- Yang, 2020, The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Res, 177, 104760, 10.1016/j.antiviral.2020.104760 · DOI · Paper page
- Schmith, 2020, The approved dose of Ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther, 108, 762, 10.1002/cpt.1889 · DOI · Paper page
- Arshad, 2020, Prioritisation of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin Pharmacol Ther, 10.1002/cpt.1909 · DOI
- Muñoz, 2018, Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg Tablet in healthy adult volunteers, PLoS Negl Trop Dis, 12, e0006020, 10.1371/journal.pntd.0006020 · DOI
- Zhang, 2008, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, 57, 524, 10.1007/s00011-008-8007-8 · DOI · Paper page
- Nandini, 2020, Interpreting diagnostic tests for SARS-CoV-2 Au, JAMA
- Ahmed, 2020, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
- Liao, 2020, Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study, Lancet Haematol, 7, e671, 10.1016/S2352-3026(20)30217-9 · DOI · Paper page
- Rajter, 2020, Use of Ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ICON Study, Chest, 159, 85, 10.1016/j.chest.2020.10.009 · DOI · Paper page
- DiNicolantonio, 2020, Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19, Open Heart, 7, e001350, 10.1136/openhrt-2020-001350 · DOI
- Hussman, 2020, Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention, Front Pharmacol, 11, 10.3389/fphar.2020.01169 · DOI · Paper page
- Mojtabavi, 2020, Interleukin-6 and severe COVID-19: a systematic review and meta-analysis, Eur Cytokine Netw, 31, 44, 10.1684/ecn.2020.0448 · DOI
- Luo, 2020, Signaling to control cytokine release syndrome in COVID-19, Trends Pharmacol Sci, 41, 531, 10.1016/j.tips.2020.06.007 · DOI · Paper page
Cited by
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001402 · Cited by 264
Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001377 · Cited by 203
Ivermectin for preventing and treating COVID-19
Popp, M., Reis, S., Schießer, S., Hausinger, R. I., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub3 · Cited by 169
Metadata
- Authors
- Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W. L., Ademuyiwa, A. O., & Omilabu, S.
- Venue
- QJM: An International Journal of Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-02-18
- Volume
- 114
- Issue
- 11
- Pages
- 780-788
- ISSN
- 0033-5622 (ISSN-L)
- 1460-2725
- 1460-2393
- OpenAlex
- W3129242298
- Cited by
- 89
- References
- 6
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- The Central Bank of Nigeria Health Sector Research and Development Intervention Scheme
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. https://app.cochat.ai/papers/10.1093/qjmed/hcab035
- The paper
- Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W. L., Ademuyiwa, A. O., & Omilabu, S. (2022). Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. QJM: An International Journal of Medicine. https://doi.org/10.1093/qjmed/hcab035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.